Compare
Candel Therapeutics, Inc. vs Acumen Pharmaceuticals, Inc. vs Kalaris Therapeutics, Inc. vs Pelthos Therapeutics Inc.
| Latest fiscal year | Candel Therapeutics, Inc. CADL | Acumen Pharmaceuticals, Inc. ABOS | Kalaris Therapeutics, Inc. KLRS | Pelthos Therapeutics Inc. PTHS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $16.80M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | 76.3% (computed) |
| Operating margin | n/a | n/a | n/a | -193.1% |
| Net margin | n/a | n/a | n/a | -257.9% |
| Net income | -$38.18M | -$121.33M | -$43.44M | -$43.32M |
| EPS (Diluted) | -$0.72 | -$2.00 | -$2.85 | -$23.04 |
| Operating cash flow | -$38.31M | -$115.54M | -$38.37M | -$22.59M |
| Free cash flow | -$38.90M | -$115.63M | -$38.57M | -$22.69M |
| Cash & equivalents | $119.73M | $53.99M | $98.05M | $17.97M |
| Total assets | $125.19M | $122.83M | $121.74M | $130.40M |
| Total liabilities | $73.27M | $52.40M | $42.92M | $91.52M |
| Shareholders' equity | $51.92M | $70.43M | $78.81M | $38.88M |
| Return on year-end equity | -73.5% | -172.3% | -55.1% | -111.4% |
| Shares outstanding | 54.90M | 60.58M | 22.90M | 3.23M |
Revenue, most recent five fiscal years
| Fiscal year | Candel Therapeutics, Inc. | Acumen Pharmaceuticals, Inc. | Kalaris Therapeutics, Inc. | Pelthos Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $125.0K Ended 2022-12-31 | n/a | $165.0K Ended 2019-12-31 | $16.80M Ended 2025-12-31 |
| 1 year earlier | $125.0K Ended 2021-12-31 | n/a | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | $125.0K Ended 2020-12-31 | n/a | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |